-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target

Benzinga·10/20/2026 12:54:04
Diffusion vocale
Guggenheim analyst Yatin Suneja reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.